News

Russia files for Sputnik vaccine registration in EU


coronavirus
Credit: CC0 Public Domain

Russian authorities have applied for registration of the Sputnik V coronavirus vaccine in the European Union, the country’s sovereign wealth fund financing the jab said Wednesday.

A spokesperson for the Russian Direct Investment Fund (RDIF) said the application with the European Medicines Agency (EMA) was lodged on Tuesday.

“It is an important milestone,” he added.

The first review of the documents filed by the RDIF is expected in February.

The EMA confirmed that a meeting with the Russian vaccine’s developer took place Tuesday “to discuss their development plan and their further engagement with the agency.”

Read:Portugal tightens lockdown as pandemic surge breaks records

But the EMA noted in a statement that “currently Sputnik V is not undergoing a rolling review.”

“EMA will communicate at the start of a rolling review procedure,” it added.

Russia in August registered Sputnik V—named after the Soviet-era satellite—months ahead of Western competitors but before the start of large-scale clinical trials, which left some experts wary.

Its developers have since said that the jab is more than 90 percent effective and Russia launched its mass vaccination campaign using the shot this week.

RDIF says that Sputnik has already been registered in a number of countries including Belarus, Venezuela, Bolivia and Algeria.

Argentina began administering second doses of Sputnik V this week, having begun its immunisation campaign in late December.

Read:Is the way we consume news detrimental to our health?

Follow the latest news on the coronavirus (COVID-19) outbreak


© 2021 AFP

Read:Youths with mood disorders who use marijuana at higher risk of death, self-harm

Citation:
Russia files for Sputnik vaccine registration in EU (2021, January 20)
retrieved 20 January 2021
from https://medicalxpress.com/news/2021-01-russia-sputnik-vaccine-registration-eu.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Previous post
Pfizer vaccine likely works against UK variant
Next post
Dutch propose curfew to rein in virus; will ban more flights